Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison Between Indicators of Plasma Atherogenicity: A Pilot Study. (October 2014)

• Record Type: Journal Article
• Authors: Kucera, Marek; Oravec, Stanislav; Hirnerova, Eva; Huckova, Nada; Celecova, Zuzana; Gaspar, Ludovit; Banach, Maciej
• Is Part Of: Angiology. Volume 65:Number 9(2014)
• Page Start: 794
• Page End: 799
• Publication Date: 2014-10
• Subjects: atorvastatin -- small-dense LDL -- atherogenic dyslipidemia -- cardiovascular risk -- apolipoprotein B -- atherogenic index of plasma; Blood-vessels -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.13005
• DOI: 10.1177/0003319713507476
• Languages: English
• ISSNs: 0003-3197

Abstract

Treatment with statins to achieve target low-density lipoprotein cholesterol (LDL-C) levels is still associated with residual risk. Lipoprotein subfraction evaluation can provide additional information regarding atherogenicity in these individuals. Patients (n = 40) with hypercholesterolemia (29 females, mean age 63 years), without previous hypolipemic treatment, were treated with atorvastatin 40 mg/d for 3 months. Atorvastatin significantly reduced total cholesterol (6.7 ± 1.0 vs 4.6 ± 1.3 mmol/L, P < .001), LDL-C (4.3 ± 1.0 vs 2.6 ± 0.9 mmol/L, P < .001), triglycerides (1.8 ± 0.9 vs 1.5 ± 1.00 mmol/L, P < .05), small-dense LDL (sdLDL) fraction 3 to 7 (0.22 ± 0.37 vs 0.09 ± 0.16 mmol/L, P < .001), and apolipoprotein B (apoB; 1.0 ± 0.2 vs 0.74 ± 0.2 g/L, P < .001). There was a negative correlation of atherogenic index of plasma (AIP) with buoyant LDL-1 and LDL-2 ( r = −.35; P < .05) and positive with sdLDL-3 to sdLDL-7 ( r = .52, P < .001). Administration of atorvastatin 40 mg/d in patients with hypercholesterolemia caused a shift in sdLDL subfractions to large, buoyant subfractions. The AIP better correlated with sdLDL than apoB levels.